RxDoctor Payments Data

Leon Oneill, DO

Cardiovascular Disease · Eatontown, NJNPI 1275723736

Payments from drug & device makers

$774in general payments, 2019–2025

Across 38 payments — averaging $20.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$116
  • Novartis$112
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$99
  • Boehringer Ingelheim$69
  • Pfizer$60
  • Kiniksa Pharmaceuticals International, PLC$52
  • plus $267 from 12 others

What the payments were for

  • Food & beverage$774100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$774 in reported general payments places this provider in the 20th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$446,698
Medicare patients
1,453
Services billed
4,688

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban561$598,628
XareltoRivaroxaban157$189,836
MultaqDronedarone Hcl39$41,756
Repatha SureclickEvolocumab39$35,369
FarxigaDapagliflozin Propanediol27$27,029
EntrestoSacubitril/Valsartan22$26,139
Praluent PenAlirocumab28$19,001
Rosuvastatin Calcium756$15,300
JardianceEmpagliflozin14$12,572
NexlizetBempedoic Acid/Ezetimibe15$11,142
Pitavastatin Calcium26$10,640
Propafenone Hcl ErPropafenone Hcl45$8,580
Metoprolol Succinate501$7,791
Dabigatran EtexilateDabigatran Etexilate Mesylate27$7,754
Atorvastatin Calcium588$6,436

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$60$598,628561 claims
Sanofi-aventis U.S. LLCMultaq$23$41,75639 claims
AstraZenecaFarxiga$18$27,02927 claims
NovartisEntresto$112$26,13922 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$33$15,39828 claims
Boehringer IngelheimJardiance$69$12,57214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Eatontown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →